Min Park

January 2, 2024

1 Min Read

22-1-2-CR-Aton-Border-Cover.png

Antibody–drug conjugates (ADCs) are complex therapeutics that offer a unique combination of selectivity and potency. Commercial demand for ADC therapeutics is projected to continue to increase while facing a very complex development, manufacturing, and supply chains challenges. Given the complexities of ADC development and manufacturing, there are clear advantages to partnering with a single contract development and manufacturing organization (CDMO) that offers a complete set of services. As ADCs continue to grab a larger share of clinical pipelines, it becomes increasingly essential to select a CDMO partner with the experience and expertise to accelerate timelines while minimizing risk.

Fill out the form below to read this special report and learn more about ADC market, growth, challenges, and solutions to accelerate ADC pipelines to market.

You May Also Like